SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-136687
Filing Date
2024-05-13
Accepted
2024-05-13 07:05:31
Documents
15
Period of Report
2024-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d802127d8k.htm   iXBRL 8-K 25469
2 EX-99.1 d802127dex991.htm EX-99.1 30547
6 GRAPHIC g802127g0511013721237.jpg GRAPHIC 3604
  Complete submission text file 0001193125-24-136687.txt   190541

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grtx-20240513.xsd EX-101.SCH 2853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20240513_lab.xml EX-101.LAB 17978
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20240513_pre.xml EX-101.PRE 11260
18 EXTRACTED XBRL INSTANCE DOCUMENT d802127d8k_htm.xml XML 3632
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

IRS No.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 24936846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)